biotechnology company says the treatment his firm has developed for COVID-19 is sitting on shelves while people continue to die, despite it being approved for use by Health Canada in the fall. Bamlanivimab was approved for interim use in Canada and for emergency use in the United States in November. Health Canada's authorization requires AbCellera to provide reports of serious adverse drug reactions, further data on the drug's effectiveness, data from ongoing clinical trials and information confirming manufacturing quality, among other requirements. "We welcome more evidence to improve care for people and look forward to more data on Bamlanivimab, and other therapies, to combat COVID-19 in B.C.," said a government statement. A statement from Alberta Health Services (AHS) also said that the proposed use of the treatment would require support from front-line medical staff in an outpatient setting.

Source: CBC News April 02, 2021 02:15 UTC